GlassScriptPhysician profile
Brice Wagner
NPI 1568037232
$3,912.25
in general payments reported to CMS, 2019-2025
31 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $1,397 · 2023: $659 · 2024: $851 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $937.16 | 2021-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $368.46 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $280.43 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $279.52 | 2023-2024 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $250.74 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.76 | 2021-2022 | |
| Pfizer INC. | $208.52 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $186.08 | 2021-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $171.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $144.26 | 2021-2025 | |
| Esperion Therapeutics, INC. | $143.36 | 2021-2025 | Nexletol |
| Abbott Laboratories | $135.13 | 2025 | Eterna |
| Cardiovascular Systems INC. | $108.72 | 2022 | |
| Jazz Pharmaceuticals INC. | $84.51 | 2022 | |
| Baxter Healthcare | $42.57 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $42.50 | 2024 | Arcalyst |
| Xeris Pharmaceuticals, INC. | $39.72 | 2024 | Keveyis |
| Regeneron Healthcare Solutions, INC. | $30.49 | 2024 | Evkeeza |
| Lilly USA, LLC | $28.35 | 2022-2025 | Zepbound, Mounjaro |
| Atricure, INC. | $26.42 | 2022 | |
| Edwards Lifesciences Corporation | $23.19 | 2025 | |
| Philips North America LLC | $20.40 | 2023 | |
| Vifor Pharma, INC. | $18.77 | 2021 | |
| Glaxosmithkline, LLC. | $17.48 | 2023 | Trelegy Ellipta |
| Bard Peripheral Vascular, INC. | $15.77 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.28 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.09 | 2023 | Arcalyst |
| Silk Road Medical, INC. | $14.60 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Astrazeneca Pharmaceuticals LP | $12.95 | 2022 | |
| Irhythm Technologies, INC. | $12.10 | 2022 | |
| Cmp Pharma, INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brice Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.